Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Merck, Ra Team Up For Cyclomimetics

by Rick Mullin
April 8, 2013 | A version of this story appeared in Volume 91, Issue 14

Merck & Co. and Ra Pharmaceuticals have entered a collaboration to develop Cyclomimetics, a class of compounds having the diversity and specificity of antibodies while retaining attributes of small-molecule drugs. Under the agreement, Ra will use its Extreme Diversity platform to develop Cyclomimetic candidates for protein targets in multiple therapeutic areas. Ra is eligible to receive up to $200 million, including unspecified up-front payments, research funding, and milestones.

Article:

This article has been sent to the following recipient:

1 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.